Lisata Therapeutics, Inc. (LSTA) — Financial statements
Income statement, balance sheet, and cash flow for Lisata Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.17↓83.0% | 1 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.02↓97.6% | 1 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 8↓29.9% | 11↓11.0% | 13↓70.7% | 43↑147.3% | 18 | |
| General & Administrative Expenses | 10↓13.6% | 12↓6.9% | 13↓8.3% | 14↑23.2% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 10↓13.6% | 12↓6.9% | 13↓8.3% | 14↑23.2% | 11 | |
| Other Expenses | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 18↓22.1% | 23↓8.9% | 26↓55.4% | 58↑98.3% | 29 | |
| Total Costs & Expenses | 18↓21.5% | 23↓8.9% | 26↓55.4% | 58↑98.3% | 29 | |
| Operating Results | ||||||
| Operating Income | -18↑18.7% | -22↑12.8% | -26↑55.4% | -58↓98.3% | -29 | |
| Depreciation & Amortization | 0.15↓16.1% | 0.17↓7.9% | 0.19↑173.9% | 0.07↑25.5% | 0.06 | |
| EBITDA | -18↑18.8% | -22↑12.9% | -26↑55.6% | -58↓98.4% | -29 | |
| EBIT | -18↑18.7% | -22↑12.8% | -26↑55.4% | -58↓98.3% | -29 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.81↓57.2% | 2↓30.9% | 3↑158.9% | 1↑596.7% | 0.15 | |
| Interest Income | 0.81↓57.2% | 2↓30.9% | 3↑158.9% | 1↑596.7% | 0.15 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.66↓59.3% | 2↓35.9% | 3↑182.9% | 0.90↑1080.3% | 0.08 | |
| Income Before Tax | -18↑15.6% | -21↑10.3% | -23↑59.1% | -57↓95.7% | -29 | |
| Income Tax Expense | -0.96↓20.6% | -0.80↑65.8% | -2↑6.0% | -2↓64.4% | -2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -17↑17.0% | -20↑4.1% | -21↑61.6% | -54↓97.4% | -27 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -17↑17.0% | -20↑4.1% | -21↑61.6% | -54↓97.4% | -27 | |
| Bottom-Line Net Income | -17↑17.0% | -20↑4.1% | -21↑61.6% | -54↓97.4% | -27 | |
| EPS (Basic) | -1.91↑20.4% | -2.40↑7.0% | -2.58↑75.4% | -10.47↓40.5% | -7.45 | |
| EPS (Diluted) | -1.91↑20.4% | -2.40↑7.0% | -2.58↑75.4% | -10.47↓40.5% | -7.45 | |
| Weighted Average Shares | 9↑4.3% | 8↑3.2% | 8↑55.8% | 5↑40.5% | 4 | |
| Weighted Average Diluted Shares | 9↑4.3% | 8↑3.2% | 8↑55.8% | 5↑40.5% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.